Loading patent…
AssigneeObi Pharma, Inc.
InventorsCheng-Der Tony YU, Jiann-Shiun LAI, I-Ju CHEN, Chiu-Chun LIN
Estimating the term…
Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.
A method for inhibiting and/or reducing the proliferation of cancer cells, the method comprising administering to a subject in need thereof an effective amount of a humanized anti-SSEA-4 antibody comprising:
A method for cancer diagnosis in a human patient, comprising:
A method for treating a human patient by monitoring prognosis of tumors in the patient, wherein the method comprising:
Dependencies are inferred from the claim text.